Bayer HealthCare's CotavanceÂ® Drug Eluting Balloon With PaccocathÂ® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon